Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Rises By 140.5%

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totalling 8,900 shares, an increase of 140.5% from the August 31st total of 3,700 shares. Based on an average daily trading volume, of 12,200 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.1% of the shares of the stock are sold short.

Indaptus Therapeutics Trading Up 22.6 %

INDP stock opened at $1.30 on Friday. The company’s 50 day moving average is $1.64 and its 200 day moving average is $2.08. The stock has a market cap of $11.10 million, a price-to-earnings ratio of -0.73 and a beta of 1.48. Indaptus Therapeutics has a 1-year low of $1.03 and a 1-year high of $3.25.

Indaptus Therapeutics (NASDAQ:INDP) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. As a group, sell-side analysts forecast that Indaptus Therapeutics will post -1.72 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Indaptus Therapeutics in a report on Monday, June 17th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.